Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 7, 2008, Pages 689-692

  Áinle, Fionnuala Ní ^a   Wong, Audris ^b   Appleby, Niamh ^a   Byrne, Brigitte ^b   Regan, Carmen ^b   Hassan, Tayyaba ^c   Milner, Marie ^c   Sullivan, Ann O ^a   White, Barry ^a   O'Donnell, James ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b Pathology Research Laboratory   (Ireland)

^c OUR LADY OF LOURDES HOSPITAL   (Ireland)

Author keywords

Low molecular weight heparin; Pregnancy; Thrombosis

Indexed keywords

TINZAPARIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PREGNANCY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 55049111238     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32830b14ef     Document Type: Article

References (16)

1. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.
3. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge MH, et al. Safety of low-motecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672.
4. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 2007; 97:505-513.
5. Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul Fibrinolysis 1998; 9:343-350.
6. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181:1113-1117.
7. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190:495-501.
8. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003; 121:12-20.
9. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymaticalty depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57:97-101.
10. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975-982.
11. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128:593-601.
12. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139:545-558.
13. Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39-43.
14. Boda Z, Laszlo P, Rejtö L, Tornai I, Pfliegler G, Blaskó G, Rak K. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 1996; 76:128.
15. Gori AM, Fedi S, Pepe G, Falciani M, Rogolino A, Prisco D, et al. Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. Br J Haematol 2002; 117:693-698.
16. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993; 23 (Suppl 1):89-98.